MA27181A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents
Derives de thiazole et d'oxazole qui modulent l'activite de ppar.Info
- Publication number
- MA27181A1 MA27181A1 MA27839A MA27839A MA27181A1 MA 27181 A1 MA27181 A1 MA 27181A1 MA 27839 A MA27839 A MA 27839A MA 27839 A MA27839 A MA 27839A MA 27181 A1 MA27181 A1 MA 27181A1
- Authority
- MA
- Morocco
- Prior art keywords
- ppar
- activity
- compounds
- thiazole
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 7 Mars 2002 60/362,402 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole et d'oxazole qui modulent l'activité de PPAR La présente invention fait connaître des composés qui modifient l'activité de PPAR. La présente invention fait connaître également des sels pharmaceutiquement acceptables des composés, des compositions pharmaceutiquement acceptables comprenant les composés ou leurs sels, et des méthodes pour leur utilisation comme agents thérapeutiques à des fins de traitement ou de prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention fait connaître également des procédés pour la préparation des composés décrits.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36240202P | 2002-03-07 | 2002-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27181A1 true MA27181A1 (fr) | 2005-01-03 |
Family
ID=27789157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27839A MA27181A1 (fr) | 2002-03-07 | 2004-08-30 | Derives de thiazole et d'oxazole qui modulent l'activite de ppar. |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030207924A1 (fr) |
EP (1) | EP1482935B1 (fr) |
JP (1) | JP2005528348A (fr) |
KR (1) | KR20040091693A (fr) |
AP (1) | AP2004003124A0 (fr) |
AR (1) | AR038881A1 (fr) |
AT (1) | ATE405260T1 (fr) |
AU (1) | AU2003206059A1 (fr) |
BR (1) | BR0308277A (fr) |
CA (1) | CA2478520A1 (fr) |
CO (1) | CO5601012A2 (fr) |
DE (1) | DE60323060D1 (fr) |
EA (1) | EA200400943A1 (fr) |
EC (1) | ECSP045285A (fr) |
ES (1) | ES2310650T3 (fr) |
HN (1) | HN2003000090A (fr) |
IS (1) | IS7377A (fr) |
MA (1) | MA27181A1 (fr) |
MX (1) | MXPA04007564A (fr) |
NO (1) | NO20044242L (fr) |
OA (1) | OA12780A (fr) |
PA (1) | PA8567801A1 (fr) |
PE (1) | PE20030989A1 (fr) |
PL (1) | PL372969A1 (fr) |
TN (1) | TNSN04168A1 (fr) |
TW (1) | TW200305403A (fr) |
UY (1) | UY27695A1 (fr) |
WO (1) | WO2003074050A1 (fr) |
ZA (1) | ZA200406068B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
SI1638551T1 (sl) * | 2003-05-19 | 2012-04-30 | Irm Llc | Imunosupresivne spojine in sestavki |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
CN1946666A (zh) | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
WO2005105736A1 (fr) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
AU2012200214B2 (en) * | 2004-05-14 | 2013-10-24 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
ZA200610650B (en) * | 2004-05-25 | 2009-04-29 | Metabolex Inc | Substituted triazoles as modulators of PPAR and methods of their preparation |
JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Pparのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
WO2006121223A1 (fr) * | 2005-05-07 | 2006-11-16 | Heon Joong Kang | Procede pour preparer des ligands de ppardelta et les composes intermediaires pour preparer ceux-ci |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
KR101333101B1 (ko) | 2005-06-30 | 2013-11-26 | 하이 포인트 파마슈티칼스, 엘엘씨 | Ppar-델타 활성제로서의 페녹시 아세트산 |
EP1916234B1 (fr) * | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Composé d'acide cyclopropanecarboxylique |
CA2621949A1 (fr) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Acides propanoiques 3-substitues par un groupement 4-hydroxyphenyle a conformation contrainte pouvant etre employes dans le traitement de troubles metaboliques |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
CA2645719A1 (fr) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composes, leur preparation et utilisation |
CA2662242C (fr) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Composes benzo-fusionnes destines a etre utilises dans le traitement de troubles metaboliques |
EP2064193A1 (fr) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Modulateurs hétérocycliques du récepteur couplé à la protéine g (gpr40) |
EP2139843B1 (fr) | 2007-04-16 | 2013-12-25 | Amgen, Inc | Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués |
MX2010003876A (es) | 2007-10-10 | 2010-12-02 | Amgen Inc | Moduladores de gpr40 bifenilo- sustituidos. |
CA2708391A1 (fr) * | 2007-12-13 | 2009-06-25 | Sri International | Ligands ppar-delta et leurs procedes d'utilisation |
CN101945848A (zh) | 2007-12-20 | 2011-01-12 | 英维沃医药有限公司 | 四取代的苯 |
EP2260017A1 (fr) | 2008-03-06 | 2010-12-15 | Amgen, Inc | Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
EP2540711A4 (fr) * | 2010-02-25 | 2014-01-22 | Snu R&Db Foundation | Dérivé de sélénazole ayant un ligand qui active le récepteur activé de la prolifération des peroxysomes (ppar), son procédé de préparation et utilisation des composés chimiques |
WO2015035171A1 (fr) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
PL331861A1 (en) * | 1996-08-19 | 1999-08-16 | Japan Tobacco Inc | Derivatives of propionic acid and their application |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
US7091225B2 (en) * | 2000-12-20 | 2006-08-15 | Smithkline Beecham Corporation | Substituted oxazoles and thiazoles as hPPAR alpha agonists |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
WO2002100403A1 (fr) * | 2001-06-07 | 2002-12-19 | Eli Lilly And Company | Modulateurs des recepteurs actives par les proliferateurs du peroxisome (ppar) |
-
2002
- 2002-12-20 US US10/324,148 patent/US20030207924A1/en not_active Abandoned
-
2003
- 2003-02-24 EP EP03702943A patent/EP1482935B1/fr not_active Expired - Lifetime
- 2003-02-24 WO PCT/IB2003/000708 patent/WO2003074050A1/fr active IP Right Grant
- 2003-02-24 ES ES03702943T patent/ES2310650T3/es not_active Expired - Lifetime
- 2003-02-24 AP APAP/P/2004/003124A patent/AP2004003124A0/en unknown
- 2003-02-24 BR BR0308277-6A patent/BR0308277A/pt not_active IP Right Cessation
- 2003-02-24 AT AT03702943T patent/ATE405260T1/de not_active IP Right Cessation
- 2003-02-24 JP JP2003572567A patent/JP2005528348A/ja not_active Abandoned
- 2003-02-24 AU AU2003206059A patent/AU2003206059A1/en not_active Abandoned
- 2003-02-24 OA OA1200400232A patent/OA12780A/en unknown
- 2003-02-24 KR KR10-2004-7013951A patent/KR20040091693A/ko not_active Application Discontinuation
- 2003-02-24 MX MXPA04007564A patent/MXPA04007564A/es active IP Right Grant
- 2003-02-24 PL PL03372969A patent/PL372969A1/xx not_active Application Discontinuation
- 2003-02-24 DE DE60323060T patent/DE60323060D1/de not_active Expired - Fee Related
- 2003-02-24 CA CA002478520A patent/CA2478520A1/fr not_active Abandoned
- 2003-02-24 EA EA200400943A patent/EA200400943A1/ru unknown
- 2003-02-27 PA PA20038567801A patent/PA8567801A1/es unknown
- 2003-03-04 PE PE2003000210A patent/PE20030989A1/es not_active Application Discontinuation
- 2003-03-05 AR ARP030100737A patent/AR038881A1/es unknown
- 2003-03-06 TW TW092104790A patent/TW200305403A/zh unknown
- 2003-03-06 UY UY27695A patent/UY27695A1/es not_active Application Discontinuation
- 2003-03-06 HN HN2003000090A patent/HN2003000090A/es unknown
-
2004
- 2004-07-29 ZA ZA200406068A patent/ZA200406068B/en unknown
- 2004-07-29 IS IS7377A patent/IS7377A/is unknown
- 2004-08-24 CO CO04082302A patent/CO5601012A2/es not_active Application Discontinuation
- 2004-08-30 MA MA27839A patent/MA27181A1/fr unknown
- 2004-09-03 TN TNP2004000168A patent/TNSN04168A1/fr unknown
- 2004-09-07 EC EC2004005285A patent/ECSP045285A/es unknown
- 2004-10-06 NO NO20044242A patent/NO20044242L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200400943A1 (ru) | 2005-02-24 |
DE60323060D1 (de) | 2008-10-02 |
OA12780A (en) | 2006-07-07 |
AP2004003124A0 (en) | 2004-09-30 |
PE20030989A1 (es) | 2003-11-29 |
AU2003206059A1 (en) | 2003-09-16 |
EP1482935A1 (fr) | 2004-12-08 |
ATE405260T1 (de) | 2008-09-15 |
IS7377A (is) | 2004-07-29 |
HN2003000090A (es) | 2004-05-05 |
AR038881A1 (es) | 2005-02-02 |
EP1482935B1 (fr) | 2008-08-20 |
ECSP045285A (es) | 2004-10-26 |
TW200305403A (en) | 2003-11-01 |
TNSN04168A1 (fr) | 2007-03-12 |
ES2310650T3 (es) | 2009-01-16 |
CO5601012A2 (es) | 2006-01-31 |
ZA200406068B (en) | 2005-09-06 |
JP2005528348A (ja) | 2005-09-22 |
WO2003074050A1 (fr) | 2003-09-12 |
US20030207924A1 (en) | 2003-11-06 |
PL372969A1 (en) | 2005-08-08 |
UY27695A1 (es) | 2003-10-31 |
CA2478520A1 (fr) | 2003-09-12 |
MXPA04007564A (es) | 2004-11-10 |
NO20044242L (no) | 2004-10-06 |
KR20040091693A (ko) | 2004-10-28 |
PA8567801A1 (es) | 2003-11-12 |
BR0308277A (pt) | 2004-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27181A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar. | |
MA27182A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar. | |
MA27189A1 (fr) | Composes qui modulent l'activite de ppar et procedes pour leur preparation | |
TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
MA26688A1 (fr) | 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
AU1850801A (en) | The combination of a serotonin reuptake inhibitor and irindalone | |
MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
MA26689A1 (fr) | Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 | |
WO2005004802A3 (fr) | Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer | |
EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
FR08C0004I2 (fr) | Composition orale d' une dose pour une libération prolongée | |
MA30231B1 (fr) | Derives de benzamides et d'heteroarenes | |
MA26954A1 (fr) | ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES | |
DZ3191A1 (fr) | Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci. | |
MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
DZ2752A1 (fr) | Composés et compositions pharmaceutiques pour le traitement du paludisme. | |
MA27135A1 (fr) | Agents antidiabetiques oraux | |
MA27692A1 (fr) | Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments | |
MA27141A1 (fr) | DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES | |
SE9903997D0 (sv) | New compounds | |
MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. |